ABSTRACT
Antiviral drugs on influenza are important in the control program of influenza. Options for influenza treatment are currently limited to using the neuraminidase inhibitors (NAIs). Given limited effectiveness of NAIs and related resistance, there remains an urgent need for the development of influenza antiviral drugs that can improve the efficacy and provide low propensity of viral resistance. Several influenza-related antiviral drugs that are currently under the late-stage clinical trials all appear differently in the mechanism of action. It is hoped that when new antiviral drugs are licensed, care and outcomes of severe influenza cases will be improved.
Subject(s)
Humans , Antiviral Agents/therapeutic use , Drug Resistance, Viral , Enzyme Inhibitors/therapeutic use , Influenza, Human/drug therapy , Neuraminidase/therapeutic useABSTRACT
Se estudiaron tres variantes del método de formación de roseta alogénica (sin suero, con suero y con suero más tratamiento con neuraminidasa) en 30 controles normales. La variante con suero más neuraminidasa mostró mennor variabilidad que las otras dos. Se aplicó dicha variante a 58 pacientes sometidos a estrés agudo: 20 con infarto agudo del miocardio, 16 sometidos a grandes intervenciones quirúrgicas, 10 politraumatizados operados y 12 politraumatizados no operados. En todos los grupos estudiados se encontró un incremento de los linfocitos formadores de roseta alogénica (linfocitos-FRA), excepto en aquéllos que habian sufrido infarto agudo del miocardio